NO20063655L - Formulation for the treatment of obesity and associated metabolic syndrome - Google Patents

Formulation for the treatment of obesity and associated metabolic syndrome

Info

Publication number
NO20063655L
NO20063655L NO20063655A NO20063655A NO20063655L NO 20063655 L NO20063655 L NO 20063655L NO 20063655 A NO20063655 A NO 20063655A NO 20063655 A NO20063655 A NO 20063655A NO 20063655 L NO20063655 L NO 20063655L
Authority
NO
Norway
Prior art keywords
formulation
obesity
treatment
metabolic syndrome
extract
Prior art date
Application number
NO20063655A
Other languages
Norwegian (no)
Inventor
Marcin Krotkiewski
Original Assignee
Bringwell Internat Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bringwell Internat Ab filed Critical Bringwell Internat Ab
Publication of NO20063655L publication Critical patent/NO20063655L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen angår formuleringer for behandling av fedme og assosierte metabolsk syndrom. Formuleringen er en kombinasjon av spesielt utvalgte vegetabilske ekstrakter: Green tea ekstrakter inneholdende Epigallocatehin galat (EGCG), Coleus forskholii ekstrakt, Betula alba ekstrakt og Guarana eller Yerba Maté ekstrakt. I følge kliniske in vivo og in vitro studier anvendes formuleringen fra oppfinnelsen som verifisert metode for hjelp i behandling av alle kjente former for fedme og assosierte sykeligheter. En av de mest viktige fordelene ved formuleringen fra oppfinnelsen, bortsett fra akselerasjon av vekttap, er forhindring av vektøkning etter avslutning av slankekuren.The invention relates to formulations for the treatment of obesity and associated metabolic syndrome. The formulation is a combination of specially selected vegetable extracts: Green tea extracts containing Epigallocatehin gallate (EGCG), Coleus forskholii extract, Betula alba extract and Guarana or Yerba Maté extract. According to clinical in vivo and in vitro studies, the formulation of the invention is used as a verified method of assisting in the treatment of all known forms of obesity and associated diseases. One of the most important advantages of the formulation of the invention, other than the acceleration of weight loss, is the prevention of weight gain upon completion of the diet.

NO20063655A 2004-01-15 2006-08-14 Formulation for the treatment of obesity and associated metabolic syndrome NO20063655L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL364411A PL209905B1 (en) 2004-01-15 2004-01-15 Formulation for treating obesity and associated metabolic syndrome
PCT/EP2005/000206 WO2005067952A1 (en) 2004-01-15 2005-01-12 Formulation for treating obesity and associated metabolic syndrome

Publications (1)

Publication Number Publication Date
NO20063655L true NO20063655L (en) 2006-09-22

Family

ID=34793496

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063655A NO20063655L (en) 2004-01-15 2006-08-14 Formulation for the treatment of obesity and associated metabolic syndrome

Country Status (13)

Country Link
US (1) US20090175969A1 (en)
EP (1) EP1708726B1 (en)
JP (1) JP2007517830A (en)
KR (1) KR100826863B1 (en)
CN (1) CN1946415A (en)
AT (1) ATE411033T1 (en)
AU (1) AU2005205031A1 (en)
CA (1) CA2584191A1 (en)
DE (1) DE602005010387D1 (en)
NO (1) NO20063655L (en)
PL (1) PL209905B1 (en)
RU (1) RU2334523C2 (en)
WO (1) WO2005067952A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2883472B1 (en) * 2005-03-23 2010-09-03 Rocher Yves Biolog Vegetale USE OF A CHLOROGENIC ACID AS A SLIMMING ACTIVE INGREDIENT
GB0520956D0 (en) 2005-10-14 2005-11-23 Med Eq As Chewing gum
PL1942874T3 (en) 2005-11-04 2014-03-31 Omega Pharma Innovation & Dev Nv Herbal composition for weight management
EP2001561A2 (en) * 2006-03-31 2008-12-17 DSMIP Assets B.V. Novel use of compounds and combinations of compunds for improving the physical appearance
MX2009004143A (en) * 2006-10-20 2009-11-26 Dow Global Technologies Inc Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome.
JP2010526043A (en) * 2007-05-04 2010-07-29 ニュートラスーティック イーティ ビジネス コンサルティング Compounds having lipolytic activity, methods for obtaining and using the same
JP2012504600A (en) * 2008-10-03 2012-02-23 シグマ・アリメントス・ソシエダ・アノニマ・デ・カピタル・バリアブレ Composition for controlling total cholesterol and LDL cholesterol and / or promoting weight loss and / or heat production
RU2465787C1 (en) * 2008-10-03 2012-11-10 СИГМА АЛИМЕНТОС, С.А. де К.В. Composition promoting regulation of total cholesterol and ldl cholesterol and/or weight loss and/or thermogenesis
FR2938735B1 (en) * 2008-11-21 2012-12-28 Holymark AMAIGRANT COMPOSITION, ESPECIALLY FOR SPORTS, ORAL ADMINISTRABLE AND FOOD SUPPLEMENT INTEGRATING SUCH A COMPOSITION.
KR20100124519A (en) * 2009-05-19 2010-11-29 (주)아모레퍼시픽 Compositions containing green tea extracts
CN102370589B (en) * 2010-08-11 2013-02-13 迪特克(济源)绿色生物科技有限公司 Slimming cream and preparation method thereof
KR101719436B1 (en) 2011-01-21 2017-03-23 라이온 가부시키가이샤 Composition for promoting lipolysis
US20130177506A1 (en) * 2011-10-27 2013-07-11 Parker E. Atkins Bio-Available Chlorogenic Acid Preparations for Supplemental Human Consumption and Use
DE202014100439U1 (en) * 2014-01-17 2014-02-25 Pm-International Ag Powdered composition for the manufacture of a food substitute
EP3285789A4 (en) * 2015-04-24 2019-01-23 Grethe Stoa Birketvedt Plant extracts for the treatment of excess weight and obesity
CN107302997A (en) * 2016-04-19 2017-10-31 林秀霞 A kind of composition for suppressing lipopexia and application thereof
CN107638569A (en) * 2016-07-21 2018-01-30 上海聿健生物科技有限公司 Strengthen the methods and applications of brown fat cell heat production efficiency
US20200367547A1 (en) * 2017-03-21 2020-11-26 Pharmachem Laboratories, Llc Controlled release of phaseolamin compositions
CN111936129A (en) * 2018-03-05 2020-11-13 纯护理专业有限责任公司 Natural combination products and methods for regulating the renal and excretory systems
KR102267472B1 (en) * 2018-10-24 2021-06-21 전남대학교산학협력단 Food composition for reducing triglyceride containing green tea catechins, food composition for improving metabolic diseases and pharmaceutical composition for preventing or treating metabolic diseases
CN113116955B (en) * 2021-02-24 2022-10-04 中国药科大学 Pharmaceutical composition containing plant extracts and application thereof
JP2024008717A (en) * 2022-07-08 2024-01-19 株式会社常磐植物化学研究所 Caffeine-removed ilex paraguariensis extract, anti-obesity composition, method for removing caffeine, and method for producing ilex paraguariensis extract
KR20240011314A (en) 2022-07-19 2024-01-26 대구한의대학교산학협력단 Composition containing guarana extract for inhibiting fat synthesis and plasma cholesterol production and Phamaceutical composition and health functional food containing the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
FR2712191B1 (en) * 1993-11-08 1996-03-08 Bioes Laboratoires Pharmaceutical or dietetic composition combining ginseng and guarana.
US5804596A (en) * 1997-02-27 1998-09-08 Sabinsa Corporation Method of preparing a forskohlin composition from forskohlin extract and use of forskohlin for promoting lean body mass and treating mood disorders
JPH10265328A (en) * 1997-03-27 1998-10-06 Nippon Flour Mills Co Ltd Cosmetic, pet food and lipase inhibitor and food containing the same
US6143301A (en) * 1998-08-28 2000-11-07 Ambi Inc. Chromium picolinate compositions and uses thereof
JP4783882B2 (en) * 1999-11-17 2011-09-28 三邦株式会社 Novel α-amylase inhibitory active substance, production method thereof and use thereof
US6610749B2 (en) * 2000-02-18 2003-08-26 Arch Development Corporation Polyhydroxylated benzene-containing compounds
WO2001074327A1 (en) * 2000-04-04 2001-10-11 Color Access, Inc. Composition for improving skin lipid barrier function
JP4795511B2 (en) * 2000-07-14 2011-10-19 日本サプリメント株式会社 Method for producing α-glucosidase inhibitor
US6797287B2 (en) * 2001-09-25 2004-09-28 Pharmachem Laboratories, Inc. Phaseolamin compositions and methods for using the same
WO2003075941A1 (en) * 2002-03-11 2003-09-18 General Nutrition Investment Company Methods for the treatment and prevention of overweight in mammals
US7279184B2 (en) * 2003-10-24 2007-10-09 Herbalscience, Llc Methods and compositions comprising Ilex

Also Published As

Publication number Publication date
WO2005067952A8 (en) 2005-11-03
EP1708726B1 (en) 2008-10-15
KR20070009562A (en) 2007-01-18
ATE411033T1 (en) 2008-10-15
CN1946415A (en) 2007-04-11
DE602005010387D1 (en) 2008-11-27
WO2005067952A1 (en) 2005-07-28
PL364411A1 (en) 2005-07-25
CA2584191A1 (en) 2005-07-28
AU2005205031A1 (en) 2005-07-28
RU2006129486A (en) 2008-02-20
JP2007517830A (en) 2007-07-05
RU2334523C2 (en) 2008-09-27
EP1708726A1 (en) 2006-10-11
PL209905B1 (en) 2011-11-30
US20090175969A1 (en) 2009-07-09
KR100826863B1 (en) 2008-05-06

Similar Documents

Publication Publication Date Title
NO20063655L (en) Formulation for the treatment of obesity and associated metabolic syndrome
Oak et al. Potential mechanisms underlying cardiovascular protection by polyphenols: Role of the endothelium
Rodriguez‐Mateos et al. Cranberry (poly) phenol metabolites correlate with improvements in vascular function: A double‐blind, randomized, controlled, dose‐response, crossover study
Rana et al. Chemistry and pharmacology of flavonoids-A review.
Wiseman The bioavailability of non-nutrient plant factors: dietary flavonoids and phyto-oestrogens
Okello et al. Inhibition of acetylcholinesterase by green and white tea and their simulated intestinal metabolites
Schini-Kerth et al. Vascular protection by natural product-derived polyphenols: in vitro and in vivo evidence
Yilmazer-Musa et al. Inhibition of α-amylase and α-glucosidase activity by tea and grape seed extracts and their constituent catechins
Pietta et al. Plant polyphenols: Structure, occurrence and bioactivity
de Jesús Romero‐Prado et al. Dietary flavonoids added to pharmacological antihypertensive therapy are effective in improving blood pressure
R. Dias et al. Promising potential of dietary (poly) phenolic compounds in the prevention and treatment of diabetes mellitus
Habtemariam Antihyperlipidemic components of Cassia auriculata aerial parts: identification through in vitro studies
Yang et al. Effect of methylated tea catechins from Chinese oolong tea on the proliferation and differentiation of 3T3-L1 preadipocyte
JP5638180B2 (en) Foods containing Salacia plant extracts and flavonoids
IL177219A0 (en) Medicinal acidic cannabinoids
WO2009032888A3 (en) Method for providing energy, relieving stress and mood enhancing benefits comprising administering a composition comprising cholecalciferol and a tea extract
Basly et al. Dietary phytoestrogens: potential selective estrogen enzyme modulators?
WO2009129260A3 (en) Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
WO2010134595A1 (en) Anti-obesity agent comprising compound containing benzotropolone ring
WO2005039493A3 (en) Herbal composition for weight control
WO2006063443A3 (en) Supplement dietary composition for promoting weight loss
Kim et al. Combination treatments with luteolin and fisetin enhance anti-inflammatory effects in high glucose-treated THP-1 cells through histone acetyltransferase/histone deacetylase regulation
WO2008106979A3 (en) Pharmaceutical compositions comprising flavonoids and xylitol
CO6410261A2 (en) DRINK THAT REDUCES THE SERIOUS CHOLESTEROL
AK et al. 21. α-Amylase and α-Glucosidase Inhibitors from Plant Extracts

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application